

Raffaele Conca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7508056/publications.pdf>

Version: 2024-02-01

24
papers

327
citations

1051969

10
h-index

939365

18
g-index

24
all docs

24
docs citations

24
times ranked

671
citing authors

#	ARTICLE	IF	CITATIONS
1	Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 1788-1791.	0.9	1
2	Therapeutic management of a symptomatic Kaposi's sarcoma patient with renal failure undergoing haemodialysis: A case report. <i>Dermatology Reports</i> , 2022, 14, 9113.	0.4	2
3	The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer. <i>Scientific Reports</i> , 2022, 12, 8244.	1.6	8
4	Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas. <i>Journal of Clinical Medicine</i> , 2021, 10, 1846.	1.0	4
5	Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. <i>Scientific Reports</i> , 2020, 10, 19281.	1.6	8
6	<p>FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10271-10278.	0.9	7
7	Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer. <i>Anti-Cancer Drugs</i> , 2020, 31, 632-636.	0.7	4
8	Clinical Outcomes and Safety of Patients Treated with Nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. <i>Current Cancer Drug Targets</i> , 2020, 20, 887-895.	0.8	8
9	Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?. <i>Medicine (United States)</i> , 2019, 98, e16249.	0.4	2
10	The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. <i>Investigational New Drugs</i> , 2019, 37, 524-530.	1.2	3
11	Lenvatinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 507-512.	1.9	14
12	Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. <i>Investigational New Drugs</i> , 2018, 36, 1110-1115.	1.2	9
13	Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer. <i>Medicine (United States)</i> , 2018, 97, e10745.	0.4	10
14	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. <i>Future Oncology</i> , 2018, 14, 41-60.	1.1	12
15	Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer. <i>Oncotarget</i> , 2018, 9, 22332-22339.	0.8	12
16	Progress and challenges in the treatment of small cell lung cancer. <i>Medical Oncology</i> , 2017, 34, 110.	1.2	25
17	Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Journal of Immunotherapy</i> , 2014, 37, 26-35.	1.2	41
18	Tumor Infiltration by T Lymphocytes Expressing Chemokine Receptor 7 (CCR7) Is Predictive of Favorable Outcome in Patients with Advanced Colorectal Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 850-857.	3.2	72

#	ARTICLE	IF	CITATIONS
19	Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen. <i>Journal of Chemotherapy</i> , 2012, 24, 245-246.	0.7	5
20	CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab. <i>Cancer Investigation</i> , 2012, 30, 65-71.	0.6	32
21	Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2011, 16, 264-269.	1.0	20
22	Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel. <i>Prostate Cancer</i> , 2011, 2011, 1-7.	0.4	14
23	Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. <i>Anti-Cancer Drugs</i> , 2010, 21, 313-319.	0.7	14
24	Therapeutic management of a symptomatic Kaposi's sarcoma patient with renal failure undergoing haemodialysis: A case report. <i>Dermatology Reports</i> , 0, , .	0.4	0